treatmentoptions4u.com

Category: Multiple Myeloma

  • Pomalidomide

    Description

    This page contains brief details about the drug pomalidomide, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Pomalidomide is an antiangiogenic agent (a drug that blocks the formation of blood vessels) which was approved for its medical use on 8th February 2013.

    Mechanism of Action of Pomalidomide

    Pomalidomide is an antiangiogenic agent that is a derivative of thalidomide. Pomalidomide works by inhibiting the formation of blood vessels that supplies nutrition to the cancer cells and facilitates the immune system attack against cancer cells. It arrests the cell cycle and induces programmed cell death of cancer cells.

    Uses of Pomalidomide

    Pomalidomide has been developed to treat Multiple myeloma and Kaposi’s sarcoma. It is effective against cancer cells that are resistant against Lenalidomide.

    Pomalidomide Dosage available Pomalidomide is available in the form of tablet and capsule in the doses 1mg, 2mg and 4mg. You shall take Pomalidomide with or without food by swallowing the tablet or capsule with water once a day. If you are on hemodialysis treatment, take Pomalidomide after hemodialysis on dialysis days.

  • Pegylated Liposomal Doxorubicin

    Description

    This page contains brief details about the drug pegylated liposomal doxorubicin, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Pegylated liposomal doxorubicin is an anticancer drug that belongs to anthracycline antibiotics. The FDA approved it in 1995 for treating certain cancers and other diseases.

    Mechanism of Action of Pegylated Liposomal Doxorubicin

    Pegylated liposomal doxorubicin is a new class of drug formulations delivered in vesicles called liposomes. The mechanism of action of doxorubicin HCl is related to its ability to bind DNA and inhibit nucleic acid synthesis. Studies have demonstrated that the drug penetrates rapidly into the cell, binds to certain proteins in DNA, and thereby inhibits cell division and nucleic acid synthesis.

    Uses of Pegylated Liposomal Doxorubicin

    Pegylated liposomal doxorubicin is used as a monotherapy for patients with metastatic breast cancer, with an increased cardiac risk associated with conventional doxorubicin. It is also indicated for advanced ovarian carcinoma in women who have failed standard first-line therapy (Platinum-and paclitaxel- based chemotherapy is the current standard first-line treatment regimen). It is also used to treat AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts (<200 CD4 lymphocytes/mm3 ) and to treat extensive mucocutaneous or visceral disease in patients who have not responded to previous cancer therapy with other medicines or whose disease has worsened despite the therapy. Other uses include combining bortezomib to treat patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.

    Pegylated Liposomal Doxorubicin Dosage available

    The drug should be administered only by physicians experienced with cancer chemotherapy. Your physician will determine the dose and frequency of administration based on the type of cancer and severity of the disease. Generally, for breast and ovarian cancer, the medicine is administered intravenously at a dose of 50 mg/m2 body surface once every 4 weeks for at least 4 courses. For treating AIDS-Kaposi Sarcoma, the drug is administered intravenously at a dose of 20 mg/m2 body surface once every two- to- three weeks only after the failure of prior systemic chemotherapy or intolerance to such therapy. For treating multiple myeloma, first bortezomib is administered at a dose of 1.3 mg/m2 as intravenous bolus on days 1, 4 , 8 and 11, every three weeks, then pegylated liposomal doxorubicin 30 mg/m2 should be administered as a 1-hr intravenous infusion on day 4 following bortezomib.

  • Epirubicin

    Description

    This page contains brief details about the drug epirubicin, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Epirubicin is an antineoplastic drug that belongs to the class anthracyclines. FDA approved epirubicin on November 15, 2006, for the treatment of breast cancer, stomach, and bowel cancer, ovarian cancer, and lung cancer.

    Mechanism of Action of Epirubicin

    Epirubicin inhibits DNA, RNA, and protein synthesis by exerting cytotoxic activity. It works by slowing or stopping the growth of the cancer cells. This medicine helps to selectively kill the cancer cells rather than the normal, healthy cells.

    Uses of Epirubicin

    Epirubicin is an intravenously administered drug. This medicine is used as adjuvant therapy in combination with other medications to treat breast cancer in patients who have had surgery to remove the tumor. It is also useful in treating breast, ovaries, stomach, bowel, and lung cancers. In addition, this medicine is also used to treat cancers of the blood-forming tissues, such as malignant lymphomas, leukemias, and multiple myeloma.

    Epirubicin Dosage available The drug should be administered only by healthcare professionals experienced with cancer chemotherapy. Your physician will determine the dose and frequency of administration based on the type of cancer and severity of the disease.  The medicine will be given as an infusion into a vein. Do not self-administer the injection.

  • Plerixafor

    Description

    This page contains brief details about the drug plerixafor, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    The U.S. FDA-approved Plerixafor is used to collect blood stem cells. Additionally, it is also used in lymphoma (WBC cancer), multiple myeloma (plasma cell cancer in bone marrow), or solid tumor On 15th December 2008.

    Mechanism of Action of Plerixafor

    Plerixafor injection works by blocking a protein called CXCR4 (chemokine receptor) on stem cells, which helps them move from the bone marrow into the bloodstream. By blocking CXCR4, Plerixafor causes the stem cells to be released into the bloodstream where the stem cells can be collected and isolated using a machine and stored for transplantation.

    Uses of Plerixafor

    Plerixafor is used to collect blood stem cells for collection, storage, and transplantation., lymphoma and multiple myeloma in adults, lymphoma or solid tumors in children (aged between 1 to 18).

    Plerixafor Dosage available

    Plerixafor injection is administered as a subcutaneous injection (under your skin). If this injection is recommended for you, it will be given by a healthcare professional. Do not self-administer. Your physician will choose the dosage and administration frequency based on the medical condition because it differs for each person.

  • Melphalan

    Description

    This page contains brief details about the drug melphalan, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Melphalan is an anticancer drug that belongs to the class of medications called alkylating agents. FDA approved it initially in 1964 for treating multiple myeloma, advanced breast cancer, ovarian cancer, polycythemia vera, childhood neuroblastoma, malignant melanoma, and soft tissue sarcoma.

    Mechanism of Action of Melphalan

    Melphalan is an alkylating agent. It exerts its cytotoxic action primarily due to the cross-linking of strands of DNA and RNA, as well as the inhibition of protein synthesis. It works by stopping or slowing the growth of cancer cells in your body.

    Uses of Melphalan

    Melphalan is available as a tablet and injection. It is used to treat multiple myeloma (a type of cancer of the bone marrow). It is also used to treat advanced ovarian cancer. It is also indicated to treat childhood neuroblastoma (cancer of the nervous system), malignant melanoma (skin cancer), and soft tissue sarcoma (cancer of the muscle, fat, fibrous tissue, blood vessels, or other supporting tissues of the body). It is also indicated to treat polycythemia vera ( a disease that increases the number of red cells in your blood. This makes the blood thicken and causes blood clots). It works by reducing the number of abnormal cells your body makes.

    Melphalan Dosage available

    Melphalan is available as a tablet and injection. Melphalan injection will be administered to you by a doctor or other healthcare professional in a hospital setting trained in cancer chemotherapy. This injection can be given as an infusion into your vein, or it will be given as a perfusion to a particular part of your body through an artery. If you are prescribed the tablet. Take the tablet at the same time, with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with water. Your doctor will decide the dose, route of administration, and duration of the therapy based on your disease status, severity, and other factors such as body weight, other disease conditions, and age.

  • Pomalidomide

  • Carfilzomib

  • Pomolidomide

  • Thalidomide

  • Lenalidomide